ArthroCare prices flotation at upper end of expectations
This article was originally published in Clinica
ArthroCare has priced its initial public offering at $14 a share, at the upper end of the range assumed in the prospectus. The Californian development-stage company intends to use the $28 million raised from the sale of 2.2 million shares to expand the manufacturing and marketing of its arthroscopic surgical equipment for knee, shoulder, elbow and ankle procedures.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.